APA

Kostev K., Schokker E. & Jacob L. (20190503). Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings. : International journal of clinical pharmacology and therapeutics.

Chicago

Kostev Karel, Schokker Emile and Jacob Louis. 20190503. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings. : International journal of clinical pharmacology and therapeutics.

Harvard

Kostev K., Schokker E. and Jacob L. (20190503). Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings. : International journal of clinical pharmacology and therapeutics.

MLA

Kostev Karel, Schokker Emile and Jacob Louis. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings. : International journal of clinical pharmacology and therapeutics. 20190503.